Previous 10 | Next 10 |
2024-07-08 08:34:52 ET Summary Novartis is close to completing its acquisition of MorphoSys, a deal valued at EUR 2.7 billion, initially agreed upon in February. Despite concerns over safety issues with MorphoSys’ lead drug, pelabresib, the likelihood of these affecting the...
2024-07-04 11:30:00 ET Summary This article will present an in-depth analysis of drugs being developed to combat obesity and related diseases. Pharmaceutical companies are highly interested in the global obesity treatment market, which is expected to exceed $100 billion by 2030. ...
2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...
2024-06-30 09:25:12 ET Summary Mereo BioPharma Group plc has seen a rebound in its stock over the past year, with positive analyst commentary in the second quarter. The company is focused on developing therapeutics for oncology and rare diseases, with a lead candidate for Osteogen...
2024-06-29 07:00:00 ET Summary The market remains near record highs with the best-ever presidential election year return and 13th-best S&P return through the first half of the year. Free cash flow yield is the best valuation metric since 1990, averaging 17.6% annual returns fo...
2024-06-27 14:14:36 ET Summary Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-d...
2024-06-22 07:00:00 ET Summary Stocks have been on fire since October lows, with many investors worried about bubbles and looming corrections. Even with the market at an all-time high, there are always extraordinary blue-chip bargains to buy. Optimal portfolio design with 11 s...
2024-06-20 04:02:15 ET More on MorphoSys, Novartis, etc. Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript) Novartis: Buy This Blue-Chip Dividend Stock On Sale Now MorphoSys: Hold Rating Until The Novartis Deal Closes Novartis, Roche facing...
2024-06-18 13:48:58 ET Summary Telix Pharmaceuticals' product revenues in full-year 2023 were $502.5 million, which was an increase of 214% from 2022 with revenues of only $160.1 million. TLX591 + best SOC is being used to treat patients with metastatic castration-resistant prosta...
2024-06-18 13:18:09 ET More on Celldex Celldex Therapeutics: Rising High, With Room For Further Growth Celldex initiated to outperform at Wolfe on barzolvolimab for skin disease Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celld...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...